While in non-transformed cells, FH binds the Activation Transcription Factor 2 (ATF2) and enhances its transcriptional activity, favoring cell cycle arrest, in cancer cells, particularly in those tumors that display a high activity of O-GlcNAc transferase (OGT) such as pancreatic adenocarcinoma (PDAC) [49], the FH/ATF2-mediated events are impaired by the O-GlcNAc glycosylation of FH. Here, ATF2 is linked to cancer.